Tumor Mutational Burden and Clinical Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy.

doi:10.1158/2767-9764.CRC-26-0255

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Tumor Mutational Burden and Clinical Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy.

Cancer research communications - 1 Aug 2026

Burgess Earle F, Brown Landon C, McCormack Michael, Liu Liang, Steuerwald Nury, Stoen Ericson, Ciampricotti Metamia, Doherty Patrick M, Williams Edward, Clark Peter E, Zhang Wei, Symanowski James T

Abstract excerpt

Pathologic complete response (pCR) after cisplatin-based neoadjuvant chemotherapy (NAC) is associated with improved outcomes in muscle-invasive bladder cancer (MIBC), but genomic predictors of benefit remain unvalidated. Based on observations in lung cancer, we hypothesized that patients with MIBC with high tumor mutational burden (TMB) would be unlikely to benefit from NAC, indicated by residual disease after...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Cisplatin

Share to Neoadjuvant Therapy

Share to Neoplasm Invasiveness

Share to Treatment Outcome

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42594312
DOI: 10.1158/2767-9764.CRC-26-0255
PMCID: PMC13519591

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.